Dakota Wealth Management Acquires New Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Dakota Wealth Management acquired a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 12,548 shares of the biotechnology company's stock, valued at approximately $463,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Proficio Capital Partners LLC acquired a new stake in Exelixis in the 4th quarter valued at $706,000. HighTower Advisors LLC boosted its stake in shares of Exelixis by 16.1% during the fourth quarter. HighTower Advisors LLC now owns 75,119 shares of the biotechnology company's stock valued at $2,501,000 after purchasing an additional 10,391 shares during the period. Farther Finance Advisors LLC grew its stake in Exelixis by 28.6% in the fourth quarter. Farther Finance Advisors LLC now owns 5,065 shares of the biotechnology company's stock worth $169,000 after purchasing an additional 1,125 shares during the period. Natixis Advisors LLC boosted its position in shares of Exelixis by 109.0% during the fourth quarter. Natixis Advisors LLC now owns 60,850 shares of the biotechnology company's stock valued at $2,026,000 after buying an additional 31,737 shares during the last quarter. Finally, Corient Private Wealth LLC raised its stake in shares of Exelixis by 111.1% in the fourth quarter. Corient Private Wealth LLC now owns 45,799 shares of the biotechnology company's stock worth $1,523,000 after buying an additional 24,108 shares during the period. 85.27% of the stock is owned by institutional investors.

Exelixis Stock Up 0.1%

EXEL stock opened at $44.87 on Friday. The business's 50-day moving average price is $43.01 and its 200-day moving average price is $38.33. Exelixis, Inc. has a twelve month low of $22.20 and a twelve month high of $49.62. The stock has a market cap of $12.24 billion, a P/E ratio of 20.40, a PEG ratio of 0.90 and a beta of 0.28.

Insider Activity

In other news, CMO Amy C. Peterson sold 72,776 shares of the business's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $45.47, for a total value of $3,309,124.72. Following the completion of the sale, the chief marketing officer directly owned 465,393 shares of the company's stock, valued at approximately $21,161,419.71. The trade was a 13.52% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Patrick J. Haley sold 34,387 shares of the business's stock in a transaction that occurred on Tuesday, May 20th. The stock was sold at an average price of $44.06, for a total value of $1,515,091.22. Following the transaction, the executive vice president owned 412,072 shares in the company, valued at $18,155,892.32. The trade was a 7.70% decrease in their position. The disclosure for this sale can be found here. Insiders sold 458,113 shares of company stock valued at $21,024,817 over the last 90 days. Company insiders own 2.82% of the company's stock.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Guggenheim set a $45.00 price target on Exelixis and gave the stock a "buy" rating in a research report on Thursday, May 15th. Wells Fargo & Company restated a "market outperform" rating on shares of Exelixis in a research report on Thursday, April 17th. HC Wainwright increased their price objective on Exelixis from $47.00 to $53.00 and gave the company a "buy" rating in a research note on Monday, June 30th. Morgan Stanley reaffirmed an "overweight" rating and set a $47.00 price objective (up previously from $40.00) on shares of Exelixis in a report on Wednesday, May 14th. Finally, Royal Bank Of Canada reaffirmed a "sector perform" rating and issued a $50.00 price objective (up previously from $45.00) on shares of Exelixis in a report on Tuesday, July 8th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $45.28.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.